AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015
Jan 6, 2015
29864_dirs_2015-01-06_affe87c7-187a-4b2f-8f98-4887cbc15831.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-01-02
Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-02 | Common Stock | M | 2291 | $73.51 | Acquired | 86791 | Direct |
| 2015-01-02 | Common Stock | S | 100 | $119.03 | Disposed | 86691 | Direct |
| 2015-01-02 | Common Stock | S | 1200 | $122.35 | Disposed | 85491 | Direct |
| 2015-01-02 | Common Stock | S | 991 | $123.12 | Disposed | 84500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-02 | Stock Option (right to buy) | $73.51 | M | 2291 | Disposed | 2024-01-01 | Common Stock (2291) | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $122.35 (range $121.75 to $122.74).
F3: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $123.12 (range $122.78 to $123.33).
F5: The option vests in 16 quarterly installments from 01/02/2014.